Skip to content

Trial Summary

The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.

Acronym:

Gilead

ACTRN/NCT /ethics:

NCT02536300

Scientific title:

Dose optimization of idelalisib in follicular lymphoma

Sponsor / Cooperative group:

Gilead Sciences

Trial & Patient Characteristics

Cancer TypeLymphoma
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream Follicular lymphoma
Cancer StageAll stages
Anticipated Start Date2016-01-14
Anticipated End Date2030-11-01

Participating Hospitals

HospitalCalvary Central Districts Hospital
Clinical Trial CoordinatorJulie Rowe
Emailjulie.rowe@calvarycare.org.au
Phone08 8239 9536
Principal InvestigatorDr Wilfrid Jaksic
Recruitment StatusRecruiting